Exclusive Industry Content 2026-2027

Infographic | Eight Challenges and Eight Agenda Sessions: Your Guide to Pharma Contract Manufacturing 2027

Infographic | Eight Challenges and Eight Agenda Sessions: Your Guide to Pharma Contract Manufacturing 2027

In this exclusive infographic, we explore the eight top challenges facing pharma contract manufacturing and match each one with a PCM 2027 agenda session designed to help address it.

Discover which sessions can help you tackle communication gaps, strengthen supply chain resilience, respond to geopolitical turbulence, navigate cost pressures, align expectations around speed, cost and quality, benchmark AI adoption, improve technology transfer, and make more informed decisions when selecting manufacturing partners.

Download the infographic to discover:

  • Which eight challenges should be on the radar of pharma and CDMO leaders
  • Which PCM 2027 session is most relevant to each challenge
  • Where to find practical discussions on resilience, partnership alignment, repricing, AI, technology transfer and CDMO selection
  • How to use the agenda to prioritise the conversations most relevant to the challenges facing your organisation

Download the infographic to identify the PCM 2027 sessions that can help you turn today's contract manufacturing challenges into practical conversations, new approaches and stronger pharma–CDMO partnerships.

Pharma IQ 2025 Market Report | Understanding the Future of the Pharma Contract Manufacturing Market

Pharma IQ 2025 Market Report | Understanding the Future of the Pharma Contract Manufacturing Market

The pharmaceutical industry is undergoing a rapid transformation, with Contract Manufacturing Organisations (CMOs) and Contract Development and Manufacturing Organisations (CDMOs) playing an increasingly vital role. Ahead of the Pharma Contract Manufacturing Summit 2025, Pharma IQ has put together a comprehensive market report, that delves into the trends, challenges, and opportunities shaping the future of pharmaceutical manufacturing.

Why Download This Report? This resource provides actionable insights for industry professionals navigating the complexities of pharmaceutical manufacturing. From building resilient supply chains to achieving sustainability goals, the report serves as a roadmap for optimising partnerships, operations, and compliance.

Download the report now to explore how you can stay ahead in a rapidly evolving market.

Key takeaways include: 

  • Market Insights: Learn how the global CMO/CDMO market is projected to reach $310.9 billion by 2030, driven by demand for outsourcing and innovative drugs.
  • Digital Transformation: Discover how AI, IoT, and smart manufacturing are revolutionising operational efficiency and regulatory compliance.
  • Sustainability: Explore how green chemistry, carbon neutrality, and sustainable packaging are redefining industry standards.
  • Geopolitical Complexities: Understand how regulations like the BIOSECURE Act and regional strategies are reshaping supply chain resilience.
  • Innovation: Learn about the role of additive manufacturing, predictive analytics, and lights-out manufacturing in driving future growth.


Guidebook | How Biotech and Mid-Sized Pharma Can Build CMO Partnerships that Can Hold Under Pressure

Guidebook | How Biotech and Mid-Sized Pharma Can Build CMO Partnerships that Can Hold Under Pressure

When you're a mid-sized pharma or biotech company, external manufacturing isn't a support function – it is your supply chain.

This How-To Guide is designed to help you build stronger, more resilient pharma–CDMO partnerships. It brings together practical frameworks for benchmarking partner performance, establishing clear quality and contractual accountability, and strengthening collaboration to navigate capacity constraints, supply chain disruption and changing market demands.

With a focus on what drives performance in practice, the guide explores how greater transparency, effective communication, robust risk management, and digital visibility can help pharma and biotech teams move beyond transactional supplier relationships towards partnerships built for the long term.

Download the guidebook to learn how to:

  • Benchmark CMO/CDMO performance across price, quality and speed, setting clear expectations and identifying where partnerships need to improve
  • Strengthen quality agreements and accountability by clarifying responsibilities, aligning KPIs and establishing effective communication between partners
  • Build more resilient external manufacturing networks that can respond to geopolitical disruption, changing capacity demands and supply chain risk
  • Improve collaboration and visibility to reduce misalignment, support operational efficiency and strengthen decision-making across external manufacturing relationships

When your product supply depends on external manufacturers, a contract alone isn't enough. You need partners who share your priorities, communicate openly and can adapt as conditions change. Download the guidebook to benchmark your partnerships, strengthen performance and build greater resilience into your pharma supply chain.

Guidebook | How Biotech and Mid-Sized Pharma can Build CMO Partnerships that Hold Under Pressure

Guidebook | How Biotech and Mid-Sized Pharma can Build CMO Partnerships that Hold Under Pressure

When you’re a mid-sized pharma or biotech company, external manufacturing isn’t a support function – it is your supply chain.

You don’t have excess capacity to fall back on. You don’t have teams dedicated solely to benchmarking suppliers or rewriting quality agreements every time regulations shift. Yet you’re expected to deliver the same reliability, compliance, and speed as companies many times your size, often in a market defined by tight capacity, rising costs, and geopolitical uncertainty.

This How-To Guide was created for organisations like yours. It brings together practical frameworks for benchmarking CMO/CDMO performance, guidance on quality agreements that actually drive accountability, real-world strategies for moving partnerships from fragile to agile, without adding unnecessary complexity or bureaucracy, and expert commentary from Tero Virtanen, Sourcing Manager, Orion Corporation.

Written with the realities of mid-sized pharma and biotech teams in mind, this guide focuses on what you can control: visibility, expectations, digital maturity, and partnership design.

Download to learn how to:

  • Benchmark CMO/CDMO performance with confidence, using metrics that reflect today’s capacity, quality, and digital realities
  • Draft and negotiate quality agreements that protect supply and accountability, not just legal positions
  • Build agile partnerships that can absorb shocks, from regulatory change to material shortages and geopolitical disruption

If your growth, pipeline, or patient access depends on external manufacturers – and you can’t afford surprises – this guide gives you the structure, language, and tools to strengthen your partnerships before pressure turns into risk.

Download the guidebook now and take control of your CMO performance in 2026.

Market Report | UNDERSTANDING THE FUTURE OF THE PHARMA CONTRACT MANUFACTURING INDUSTRY 2026

Market Report | UNDERSTANDING THE FUTURE OF THE PHARMA CONTRACT MANUFACTURING INDUSTRY 2026

When you’re managing external manufacturing today, the pressure isn’t abstract; it’s daily, immediate, and growing. Capacity is tightening across sterile and biologics, global regulations are shifting faster than contracts can keep up, and geopolitical instability is reshaping where medicines can be made, sourced, and shipped.

This is exactly why the 2026 Pharma Contract Manufacturing Market Report was built: to give you the clarity, the benchmarks, and the competitive intelligence you need to make confident decisions in a market that isn’t standing still.

With expert commentary from Christian Simon, Head of Technical Transfer, External Manufacturing, Sanofi, and Philip Coetzee, Director, CMO Management, Daiichi Sankyo, they both share their insights on how to deliver reliability with less buffer, innovation with fewer resources, and agility with partners facing the same constraints you are.

Download to learn more about:

  • Market Shifts You Need to Know: The global CMO/CDMO market is accelerating toward $319.6B by 2029, with biotech outsourcing growing more than 12% year-on-year.
  • Risks You’re Navigating Every Day: Supply chain disruptions have increased by 38% in the past 12 months, driven by tariffs, sanctions, and regional realignments.
  • What Makes Partnerships Actually Work in 2026: Strong alliances are built on shared visibility, structured communication, and joint planning, not just SLAs. Pharma teams that implement integrated review cycles with CMOs report 20-30% fewer delays and higher tech-transfer success.
  • Innovation You Can’t Afford to Ignore: Digital twins and AI-based planning are improving cycle time by 15-40% in organisations already adopting them. Single-use systems continue to gain ground, reducing cleaning-related downtime by up to 60%.

If you’re operating in an environment where a single disruption – a delayed material, a missed forecast, an unexpected deviation – can ripple across your entire supply network. This report gives you the insights to anticipate those pressures, benchmark your partnerships, and build agility into your operations before the next disruption hits. Equip yourself with the intelligence to strengthen your CMO/CDMO relationships, negotiate with confidence, and protect your supply chain in the year ahead.

Download your copy now and stay ahead of the pressures reshaping pharma contract manufacturing.

Report | Smart Manufacturing in 2026: Technology, Trends, and Insights for CMOs

Report | Smart Manufacturing in 2026: Technology, Trends, and Insights for CMOs

If you’re managing external manufacturing today, technology is already shaping your risk, your timelines, and your relationships with CMOs and CDMOs. Digital maturity gaps, uneven automation, and rising regulatory expectations mean that how your partners invest in technology now directly impacts supply resilience and quality outcomes.

This technology report gives you a clear view of how smart manufacturing, AI, automation, and digital quality systems are reshaping pharma contract manufacturing, and what this means for your CMO strategy in the year ahead.

Download this report to understand:

  • Which manufacturing technologies are genuinely improving reliability, compliance, and capacity
  • How digitalisation is changing pharma–CMO collaboration, visibility, and decision-making
  • Where technology gaps in your supply network could become future risk     

This report sets the context for the conversations happening at Pharma Contract Manufacturing 2026 (23–25 March, Berlin), where pharma and CMO leaders will go deeper into how technology, partnerships, and capacity planning must evolve together under pressure.

Download the report now, and come to PCM 2026 ready to challenge assumptions, benchmark your partners, and engage in more informed, practical discussions with your manufacturing network.